DCM
AQST icon

Dupont Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Dupont Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-36,752
Closed -$191K – 1723
2021
Q1 		$191K Sell
36,752
-7,537
-17% -$40.1K ﹤0.01% 1282
2020
Q4 		$237K Buy
44,289
+12,196
+38% +$73.1K 0.01% 1106
2020
Q3 		$156K Buy
+32,093
New +$210K ﹤0.01% 1149

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Dupont Capital Management's AQST Position: Q2 2021 in Review

Dupont Capital Management sold out of Aquestive Therapeutics (AQST) in Q2 2021, closing a stake of 36,752 shares — an estimated $191K sold.

Dupont Capital Management first reported a position in AQST in Q3 2020 and held it in 3 quarters. The position peaked at $237K in Q4 2020. 60 funds tracked by Wall St. Rank hold AQST as of Q2 2021.

  • Dupont Capital Management reported no remaining Aquestive Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Dupont Capital Management sold 36,752 Aquestive Therapeutics shares in Q2 2021, an estimated $191K.
  • Dupont Capital Management first reported a position in Aquestive Therapeutics in Q3 2020 and held it in 3 quarters.
  • Dupont Capital Management's Aquestive Therapeutics position peaked at $237K in Q4 2020.
  • 60 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2021.

Based on Dupont Capital Management's 13F filing for Q2 2021, filed 30 Jul 2021.